Delaware
No.
|
|
11-2644611
|
(State
or other jurisdiction
|
|
(IRS
Employer Identification No.)
|
of
incorporation or organization)
|
|
|
Part
I
|
|
|
|
Part
II
|
|
|
|
Part
III
|
|
|
|
· |
GI
Device (Icon GI)-
|
· |
Bovie
Button
|
·
|
Product
development.
|
·
|
Product
testing.
|
·
|
Product
labeling.
|
·
|
Product
storage.
|
·
|
Pre-market
clearance or approval.
|
·
|
Advertising
and promotion.
|
·
|
Product
traceability, and
|
·
|
Product
indications.
|
·
|
Quality
System Regulations.
|
·
|
Medical
device reporting regulations, and
|
·
|
FDA
restrictions on promoting products for unapproved or off-label
uses.
|
·
|
Description
of the device and its components,
|
·
|
Safety
and performance of the device,
|
·
|
Clinical
evaluations with respect to the device,
|
·
|
Methods,
facilities and quality controls used to manufacture the device,
and
|
·
|
Proposed
labeling for the device.
|
·
|
Results
of bench and laboratory tests, animal studies, and clinical studies,
|
·
|
A
complete description of the device and its components,
|
·
|
A
detailed description of the methods, facilities and controls used
to
manufacture the device, and
|
·
|
Proposed
labeling.
|
2005
|
|
High
|
Low
|
|
|
|
|||
1st
Quarter
|
$
|
3.05
|
$
|
2.20
|
2nd
Quarter
|
|
2.54
|
1.95
|
|
3rd
Quarter
|
|
2.44
|
1.60
|
|
4th
Quarter
|
|
2.99
|
2.05
|
|
|
|
|
|
|
2004
|
High
|
Low
|
||
|
|
|
||
1st
Quarter
|
$
|
3.70
|
$
|
2.32
|
2nd
Quarter
|
|
3.10
|
2.31
|
|
3rd
Quarter
|
|
3.00
|
2.06
|
|
4th
Quarter
|
|
2.72
|
2.25
|
|
|
|
Analysis
of 2005/2004
|
|
|
Percentage
change in dollar amounts
|
|
2005
|
2004
|
%
|
2004/2005
|
|
%
|
%
|
Change
|
%
|
|
Sales
|
100.0
|
100.0
|
0
|
(1.4)
|
Cost
of sales
|
62.6
|
61.1
|
1.5
|
.1
|
Gross
profit
|
37.4
|
38.9
|
(1.5)
|
(3.8)
|
Other
costs:
|
||||
R
& D
|
4.9
|
4.4
|
.5
|
8.6
|
Professional
fees
|
2.2
|
2.0
|
.2
|
7.6
|
Labor
|
9.9
|
9.6
|
.3
|
1.7
|
SGA
|
17.6
|
16.4
|
1.2
|
9.4
|
Development
cost - joint venture
|
.8
|
.2
|
.6
|
310.3
|
Total
other costs
|
35.4
|
32.6
|
2.8
|
8.6
|
|
||||
Income
from operations
|
2.0
|
6.2
|
(4.2)
|
(68.2)
|
|
||||
Other
income/expense
|
.1
|
1.2
|
(1.1)
|
(89.6)
|
|
||||
Net
income before taxes and minority expense
|
2.1
|
7.4
|
(5.3)
|
(71.9)
|
Income
tax expense
|
(.8)
|
(2.2)
|
(1.4)
|
(69.7)
|
Income
tax benefit
|
.7
|
2.2
|
1.5
|
(75.6)
|
|
||||
Net
income after taxes
|
2
|
7.4
|
(5.4)
|
(73.1)
|
Net
Sales (in thousands)
|
Percentage
|
|||||||||||
Increase
|
Change
|
|||||||||||
2005
|
2004
|
(Decrease)
|
2005/2004
|
|||||||||
Domestic/international
sales in thousands)
|
||||||||||||
Domestic
|
|
$
|
16,830
|
17,506
|
|
(676
)
|
|
|
(4)
|
%
|
||
International
|
|
|
3,381
|
2,989
|
|
392
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total
net sales
|
|
$
|
20,211
|
20,495
|
|
(284)
|
|
(1)
|
|
|
||
|
|
|
|
|
|
|
|
|
||||
Product
line sales:
|
|
|
|
|
|
|
|
|
||||
Electrosurgical
|
|
$
|
12,191
|
12,684
|
|
(493)
|
|
|
(4)
|
|
|
|
Cauteries
|
|
|
5,462
|
5,460
|
|
2
|
|
|
--
|
|
|
|
Other
|
|
|
2,558
|
2,351
|
|
207
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total
net sales
|
|
$
|
20,211
|
20,495
|
|
(284)
|
|
|
(1)
|
|
|
|
|
Payment
Period
|
|
|
2006
|
2007
|
2008
|
2009
|
|
Long-term
debt
|
348
|
-0-
|
-0-
|
-0-
|
Operating
leases
|
142
|
135
|
115
|
-0-
|
Unconditional
purchase obligations
|
2,587
|
-0-
|
-0-
|
-0-
|
|
|
Amount
of Commitment
|
|
|||||||
|
|
Total
|
Expiration
Per Period
|
|
||||||
|
|
Amount
|
Less
than
|
In
excess of
|
|
|||||
|
|
Committed
|
1
year
|
1
year
|
|
|||||
Secured
revolving credit agreement and other lines of credit
|
|
$
|
1.5
|
|
$
|
1.5
|
|
|
-0-
|
|
Name
|
Position
|
Director
Since
|
Andrew
Makrides
|
Chairman
of the Board, President, CEO and
|
December
1982
|
Chief
Financial Officer
|
||
J.
Robert Saron
|
President
of Aaron Medical Industries,Inc. and Director
|
August
1994
|
George
Kromer
|
Director
|
October
1995
|
Brian
Madden
|
Director
|
September
2003
|
Moshe
Citronowicz
|
Executive
Vice President and Chief Operating Officer
|
--
|
Michael
Norman
|
Director
|
September
2004
|
Randy
Rossi
|
Director
|
September
2004
|
Long
Term
|
||||
Annual
Compensation
|
Compensation
|
|||
(a)
|
(b)
|
I
|
(d)
|
(g)
|
Name
and Principal Position
|
Year
|
Salary($)
|
Bonus($)
|
Securities
Underlying Options/ SARs(#)
|
|
|
|
|
|
Andrew
Makrides
President,
CEO,
Chairman
of
the
Board and Chief Financial Officer (B)
|
2005
|
$186,418
|
3,428
|
25,000
|
2004
|
$167,320
|
3,189
|
25,000
|
|
2003
|
$158,406
|
2,967
|
110,000
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
J.
Robert Saron
President
of Aaron
Medical
and
Director
|
2005
|
$256,173
|
4,854
|
25,000
|
2004
|
$233,036
|
4515
|
25,000
|
|
2003
|
$219,786
|
4,200
|
110,000
|
|
|
|
|
||
|
|
|
||
|
|
|
|
|
Moshe
Citronowicz
Executive
Vice
President-
Chief
Operating
Officer
|
2005
|
$193,451
|
3,567
|
25,000
|
2004
|
$170,766
|
3,318
|
25,000
|
|
2003
|
$158,637
|
3,086
|
110,000
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
Charles
Peabody (A)
|
2005
|
$50,515
|
25,000
|
|
Chief
Financial
|
2004
|
$81,825
|
1,579
|
25,000
|
Officer
|
2003
|
$77,221
|
1,532
|
60,000
|
|
|
|
|
|
|
|
|
|
|
Individual
Grants
|
Potential
Realizable
Value
at Assumed Annual Rates of Stock Price Appreciation for Option
Term
|
||||
Name
(a)
|
Number
of Securities
Underlying
Options Granted
(b)(1)
|
%
of Total Options
Granted
to Employees in 2005
(c)
|
Exercise
or Base Price per Share
(d)
|
Expiration
Date
(e)
|
5%($)
(f)
|
10%($)
(g)
|
Charles
Peabody(CFO)(3)
|
25,000
|
5.85%
|
2.25
|
|||
Moshe
Citronowicz(COO)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
35,375
|
89,648
|
J.
Robert Saron(2)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
35,375
|
89,648
|
Andrew
Makrides(CEO)(CFO)
|
25,000
|
5.85%
|
2.25
|
05/05/15
|
35,375
|
89,648
|
Plan
category
|
Number
of Securities
to
be issued upon
exercise
of
outstanding
options,
|
Weighted-average
exercise
price of
outstanding
options,
warrants
and rights
|
Number
of securities
remaining
available
for
future issuance
under
equity
compensation
plans
|
Equity
compensation Plans approved by Security holders
|
|
|
|
3,751,370
|
$1.14
|
483,300
|
|
Total
|
4,168,870
|
$1.25
|
483,300
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
||
Name
|
Shares
Acquired on Exercise (#)
|
Value
Realized ($)
|
Number
of Securities Underlying Unexercised Options/SARs at December 31,
2005
(#)
|
Value
of Unexercised In-the Money Options/SARs at December 31,
2005($)
|
||
Exercisable
|
Unexercisable
|
Exercisable
|
Unexercisable
|
|||
Andrew
Makrides
|
-
|
-
|
535,000
|
-
|
1,080,800
|
-
|
Alfred
Greco (2)
|
-
|
-
|
-
|
-
|
||
George
Kromer
|
-
|
-
|
440,000
|
-
|
868,325
|
-
|
Moshe
Citronowicz
|
25,000
|
72,500
|
465,000
|
-
|
952,200
|
-
|
Rob
Saron
|
-
|
-
|
555,000
|
-
|
1,141,650
|
-
|
Brian
Madden
|
-
|
-
|
85,000
|
-
|
66,300
|
-
|
Michael
Norman
|
-
|
-
|
60,000
|
-
|
46,800
|
-
|
Charles
Peabody(3)
|
-
|
-
|
-
|
-
|
||
Randy
Rossi
|
-
|
-
|
50,000
|
-
|
39,500
|
-
|
|
|
|
|
|||
Total
|
25,000
|
72,500
|
2,190,000
|
-
|
4,195,575
|
-
|
(a) |
Upon
the death of the Executive and the Executive’s estate shall be paid the
basic annual compensation due the Employee pro-rated through the
date of
termination.
|
(b) |
By
the Resignation of the Executive at any time upon at least thirty
(30)
days prior written notice to Bovie; and Bovie shall be obligated
to pay
the Employee the basic annual compensation due him pro-rated to
the
effective date of termination,
|
(c) |
By
Bovie, for cause if during the term of the Employment Agreement
the
Employee violates the provisions of Paragraph 12 hereof, or is
found
guilty in a court of law of any crime of moral
turpitude.
|
(d) |
By
Bovie, without cause, with the majority approval of the Board of
Directors, at any time upon at least thirty (30) days prior written
notice
to the Executive: and Bovie shall be obligated to pay the Executive
compensation currently in effect including all bonuses, accrued
or
prorate, and expenses up to the date of termination. Thereafter,
for the
period remaining under the contract, Bovie shall pay the Executive
the
salary then in effect at the time of termination payable weekly.
Employee
shall not have to account for other compensation other sources
or
otherwise mitigate his damages due to such
termination.
|
(e) |
If
Bovie terminates the agreement, without cause, or fails to meet
its
obligations to the Executive on a timely basis, or if there is
a change in
the control of Bovie, the Executive may elect to terminate his
employment
agreement. Upon any such termination or breach of any of its obligations
under the Employment Agreement, Bovie shall pay the Executive a
lump sum
severance equal to three times the annual salary and bonus in effect
the
month preceding such termination or breach as well as any other
sums which
may be due under the terms of the Employment Agreement up to the
date of
termination.
|
Bovie
Medical Corporation
|
||||
December
31, 2005
|
||||
|
|
|
|
|
|
Contract
|
Expiration
|
Current
|
Auto
|
|
Date
|
Date(1)
|
Base
Pay
|
Allowance
|
|
|
|
|
|
Andrew
Makrides
|
01/01/98
|
1/31/2009(1)
|
$178,274
|
$
6,067
|
J.
Robert Saron
|
01/01/98
|
1/31/2009(1)
|
252,410
|
6,067
|
Moshe
Citronowicz
|
01/01/98
|
1/31/2009(1)
|
185,482
|
6,067
|
(1) |
Includes
total extensions for six years- Salaries increase annually pursuant
to a
contract formula. In the event of a change in control, each officers’
contract contains an option for each respective officer to resign
and
receive 3 years salary.
|
|
Number
of Shares
|
|
|
|
|
Nature
of
|
Percentage
of
|
||
Name
and Address
|
Title
|
Owned
(i)
|
Ownership
|
Ownership(i)
|
The
Frost National Bank
|
Common
|
1,000,000
|
Beneficial
|
5.5%
|
FBO
Renaissance
|
||||
US
Growth Investment
|
||||
Trust
PLC.
|
||||
Trust
no. W00740100
|
||||
|
||||
The
Frost National Bank
|
Common
|
1,000,000
|
Beneficial
|
5.5%
|
FBO,
BFS US Special
|
||||
Opportunities
Trust PLC.
|
||||
Trust
no. W00118000
|
||||
|
||||
Directors
and Officers
|
||||
Andrew
Makrides
734
Walt Whitman Road
Melville,
NY 11746
|
Common
|
850,800(ii)
|
Beneficial
|
5.8%
|
|
||||
George
Kromer
P.O.
Box 188
Farmingville,
NY 11738
|
Common
|
440,000(iii)
|
Beneficial
|
3.0%
|
J.
Robert Saron
7100
30th
Avenue North
St.
Petersburg, FL 33710
|
Common
|
799,363(iv)
|
Beneficial
|
5.5%
|
|
||||
Moshe
Citronowicz
7100
30th
Avenue North
St.
Petersburg, FL 33710
|
Common
|
639,591
(v)
|
Beneficial
|
4.4%
|
Brian
Madden
300
Garden City Plaza
Garden
City, NY 11530
|
Common
|
85,000
(vi)
|
Beneficial
|
.6%
|
|
||||
Mike
Norman
|
Common
|
60,000(vii)
|
Beneficial
|
.4%
|
410
Jericho Tpke,
|
||||
Jericho,
NY
|
||||
|
||||
Randy
Rossi
|
Common
|
60,000(viii)
|
Beneficial
|
.4%
|
2641
Kelliwood Circle
|
||||
Shrevesport,
LA
|
||||
|
||||
Officers
and Directors as a group(7 Persons)
|
2,934,754(ix)
|
18%
|
Exhibit
4.2
|
Registration
Rights Agreement dated May 8, 1998
|
Exhibit
4.3
|
Assignment
of Registration Rights Agreement dated September, 2004
|
Exhibit
10.1
|
Joint
Venture Agreement dated February 25, 2000
Between
Bovie Medical Corporation and Jump Agentur fur
Elektrotechnik
GmBH
|
Exhibit
10.2
|
Agreement
between Bovie Medical Corporation and Arthrex Inc. dated June
2002
|
Exhibit
10.3
|
Distribution
and Service Center Agreement between Bovie Medical Corp and
Symbol Medical
Limited dated December 31, 2004
|
Exhibit
10.4
|
Employment
Agreement- Andrew Makrides
|
Exhibit
10.5
|
Employment
Agreement-Robert J. Saron
|
Exhibit
10.6
|
Employment
Agreement-Moshe Citronowicz
|
Exhibit
10.7
|
Amended
Employment Agreement between Bovie and Andrew Makrides dated as
of January
6, 2004.
|
Exhibit
10.8
|
Amended
Employment Agreement between Bovie and J. Robert Saron dated as
of January
6, 2004.
|
Exhibit
10.9
|
Amended
Employment Agreement between Bovie and Moshe Citronowciz dated
as of
January 6, 2004.
|
Exhibit
10.10
|
License
Agreement between Bovie and Emergency Medicine Innovations, LLC
dated
October 22, 2004.
|
_____________________
|
|
|
|
2005
|
2004
|
|
|||
Audit
Fees (1)
|
|
$
|
130,027
|
|
$
|
133,442
|
|
|
|
|
|
|
|
|
|
Non-Audit
Fees:
|
|
|
|
|
|
|
|
Related
Fees(2)
|
|
|
25,000
|
|
|
--
|
|
Tax
Fees(3)
|
|
|
5,000
|
|
|
5,000
|
|
All
other Fees(4)
|
|
|
--
|
|
|
--
|
|
Total
Fees paid to Auditor
|
|
$
|
160,027
|
|
$
|
138,442
|
|
|
Bovie
Medical Corporation
|
|
|
|
|
|
By:
/s/ Andrew Makrides
|
|
Andrew
Makrides
|
|
President
|
|
Chairman
of the Board
|
Chief
Financial Officer
|
Contents
|
|
|
|
|
|
|
|
BLOOM
& CO., LLP 50 CLINTON STREET. HEMPSTEAD. NEW YORK 11550:
|
TEL:
516 - 486-5900
|
CERTIFIED
PUBLIC ACCOUNTANTS
|
FAX:
516 - 486-5476
|
|
|
STEVEN
BLOOM, CPA
FREDERICK
PAUKER, CPA
SIROUSSE
TABRIZTCHI, Ph.D. CPA
|
MEMBER
OF AMERICAN INSTITUTE OF
CERTIFIED
PUBLIC ACCOUNTANTS
|
|
2005
|
2004
|
|||||
Current
assets:
|
|
|
|||||
|
|
|
|||||
Cash
|
$
|
1,295,266
|
$
|
2,294,746
|
|||
Trade
accounts receivable, net
|
2,316,761
|
1,954,287
|
|||||
Inventories
|
2,996,832
|
2,001,637
|
|||||
Prepaid
expenses
|
335,492
|
328,765
|
|||||
Deferred
tax asset
|
386,200
|
386,200
|
|||||
|
|||||||
|
|||||||
Total
current assets
|
7,330,551
|
6,965,635
|
|||||
|
|||||||
Property
and equipment, net
|
2,595,641
|
2,116,324
|
|||||
|
|||||||
Other
assets:
|
|||||||
|
|||||||
Repair
parts
|
--
|
124,363
|
|||||
Brand
name/Trademark
|
1,509,662
|
1,509,662
|
|||||
Purchased
technology (net)
|
33,663
|
88,572
|
|||||
License
rights
|
280,000
|
350,000
|
|||||
Deposits
|
21,215
|
14,445
|
|||||
|
1,844,540
|
2,087,042
|
|||||
|
|||||||
Total
Assets
|
$
|
11,770,732
|
$
|
11,169,001
|
|||
|
|||||||
|
|||||||
The
accompanying notes are an integral part of the financial
statements.
|
Current
liabilities:
|
2005
|
2004
|
|||||
|
|||||||
Accounts
payable
|
$
|
868,212
|
$
|
620,151
|
|||
Accrued
expenses and other liabilities
|
471,006
|
568,482
|
|||||
Customers
deposits
|
--
|
36,000
|
|||||
Deferred
Revenue
|
141,586
|
157,844
|
|||||
Current
maturities of long term debt
|
348,328
|
31,668
|
|||||
|
|||||||
Total
current liabilities
|
1,829,132
|
1,414,145
|
|||||
|
|||||||
Mortgage
Payable-Non current
|
--
|
348,325
|
|||||
Minority
interest
|
140,000
|
150,000
|
|||||
Stockholders'
equity:
|
|||||||
|
|||||||
Preferred
stock 10,000,000 shares
authorized,
none outstanding
|
|||||||
|
|||||||
Common
stock par value $.001;
40,000,000
shares authorized,
14,040,728
and 13,862,128
issued
and outstanding
on
December 31, 2005 and
December
31, 2004 respectively,
|
14,059
|
13,881
|
|||||
Additional
paid in capital
|
20,530,090
|
20,391,407
|
|||||
Accumulated
deficit
|
(10,742,549
|
)
|
(11,148,757
|
)
|
|||
Total
stockholders' equity
|
9,801,600
|
9,256,531
|
|||||
|
|||||||
Total
liabilities and stockholders' equity
|
$
|
11,770,732
|
$
|
11,169,001
|
|||
The
accompanying notes are an integral part of the financial
statements.
|
|
|
|
|||||
|
2005
|
2004
|
|||||
|
|
||||||
Sales
|
$
|
20,211,141
|
20,495,101
|
||||
Cost
of sales
|
12,649,209
|
12,638,161
|
|||||
|
|||||||
Gross
Profit
|
7,561,932
|
7,856,940
|
|||||
|
|||||||
Other
costs:
|
|||||||
Research
and development
|
985,807
|
907,389
|
|||||
Professional
services
|
447,346
|
415,606
|
|||||
Salaries
and related costs
|
2,010,599
|
1,977,053
|
|||||
Selling,
general and administration
|
3,553,022
|
3,249,050
|
|||||
Development
cost - joint venture
|
161,190
|
39,286
|
|||||
|
|||||||
Total
other costs
|
7,157,964
|
6,588,384
|
|||||
|
|||||||
Income
from operations
|
403,968
|
1,268,556
|
|||||
|
|||||||
Other
income and (expense):
|
|||||||
Gain
from involuntary conversion of fixed assets
|
245,264
|
||||||
Interest
income
|
46,959
|
3,263
|
|||||
Interest
expense
|
(22,703
|
)
|
(
15,090
|
)
|
|||
|
24,256
|
233,437
|
|||||
|
|||||||
Net
income before income tax and minority expense
|
428,224
|
1,501,993
|
|||||
Minority
Interest in expense
|
10,000
|
10,000
|
|||||
Income
tax expense
|
(164,016
|
)
|
(541,000
|
)
|
|||
Income
tax benefit
|
132,000
|
541,000
|
|||||
|
|||||||
Net
income
|
$
|
406,208
|
$
|
1,511,993
|
|||
|
|||||||
The
accompanying notes are an integral part of the financial
statements.
|
|
2005
|
2004
|
|||||
|
|
|
|||||
Basic
earnings per common share
|
$
|
.03
|
$
|
.11
|
|||
|
|||||||
Diluted
earnings per common share
|
.03
|
.09
|
|||||
|
|||||||
Weighted
average number
|
|||||||
of
common shares outstanding
|
13,923,134
|
13,755,552
|
|||||
|
|||||||
Incremental
items:
|
|||||||
Stock
options
|
1,827,150
|
2,422,329
|
|||||
|
|||||||
Diluted
weighted average
|
|||||||
common
shares outstanding
|
15,750,284
|
16,177,881
|
|||||
|
|||||||
The
accompanying notes are an integral part of the financial
statements.
|
|
|
|
|
|
|
|
|
Options
|
Common
|
Paid-
|
|||
|
Outstanding
|
Shares
|
Value
|
in
Capital
|
Deficit
|
Total
|
January
1, 2004
|
3,988,800
|
13,464,528
|
$13,482
|
$20,097,095
|
$(12,660,750)
|
$7,449,827
|
|
|
|
|
|
|
|
Options
granted
|
370,000
|
--
|
--
|
--
|
--
|
--
|
|
||||||
Options
exercised
|
(397,600)
|
397,600
|
399
|
294,312
|
--
|
294,711
|
|
||||||
Options
forfeited
|
(10,000)
|
--
|
--
|
--
|
--
|
--
|
|
||||||
Income
for period
|
--
|
--
|
--
|
--
|
1,511,993
|
1,511,993
|
|
||||||
December
31, 2004
|
3,951,200
|
13,862,128
|
$13,881
|
$20,391,407
|
$(11,148,757)
|
$9,256,531
|
|
|
|
|
|
|
|
Options
granted
|
427,500
|
|||||
Options
exercised
|
(178,600)
|
178,600
|
178
|
138,683
|
138,861
|
|
Options
foreited
|
(31,230)
|
|||||
Income
for period
|
406,208
|
406,208
|
||||
December
31, 2005
|
||||||
4,168,870
|
14,040,728
|
$14,059
|
$20,530,090
|
$(10,742,549)
|
$9,801,600
|
|
|
2005
|
2004
|
|||||
Cash
flows from operating activities:
|
|||||||
|
|||||||
Net
income
|
$
|
406,208
|
$
|
1,511,993
|
|||
Adjustments
to reconcile
|
|||||||
net
income to net cash provided
|
|||||||
by
operating activities:
|
|||||||
|
|||||||
Depreciation
and amortization
|
545,876
|
395,119
|
|||||
Write
down of inventories and parts
|
303,872
|
||||||
Write
down development cost
|
|||||||
Involuntary
conversion of fixed assets
|
(
245,264
|
)
|
|||||
|
|||||||
Change
in assets and liabilities:
|
|||||||
Trade
receivables
|
(362,474
|
)
|
(322,106
|
)
|
|||
Prepaid
expenses
|
(
6,727
|
)
|
61,260
|
||||
Inventories
and parts
|
(870,832
|
)
|
249,503
|
||||
Accounts
payable
|
248,061
|
(59,641
|
)
|
||||
Accrued
expenses
|
(133,476
|
)
|
149,251
|
||||
Deferred
Revenue
|
(
16,258
|
)
|
|||||
|
|||||||
Total
adjustments
|
(595,830
|
)
|
531,994
|
||||
|
|||||||
|
|||||||
Net
cash (applied to) provided by operations
|
$
|
(189,622
|
)
|
$
|
2,043,987
|
||
|
|||||||
|
|||||||
The
accompanying notes are an integral part of the financial
statements.
|
|
2005
|
2004
|
|||||
Net
cash (applied to) provided by operating activities
|
$
|
(189,622
|
)
|
$
|
2,043,987
|
||
|
|||||||
Cash
flows from investing activities:
|
|||||||
|
|||||||
(Increase)
in fixed assets
|
(908,283
|
)
|
(606,505
|
)
|
|||
Decrease(Increase)in
security deposits
|
(
6,770
|
)
|
(
4,975
|
)
|
|||
Purchase
of technology
|
(
2,001
|
)
|
--
|
||||
Involuntary
conversion of fixed assets
|
296,735
|
||||||
|
|||||||
Net
cash (used in) investing activities
|
(917,054
|
)
|
(314,745
|
)
|
|||
|
|||||||
Cash
flows from financing activities;
|
|||||||
|
|||||||
Sale
of common stock
|
138,861
|
290,425
|
|||||
Reduction
in subscription receivable
|
4,286
|
||||||
Reduction
in mortgage
|
(31,665
|
)
|
(35,344
|
)
|
|||
|
|||||||
Net
cash (provided by) financing activities
|
107,196
|
259,367
|
|||||
|
|||||||
Net
increase(decrease) in cash
|
(999,480
|
)
|
1,988,609
|
||||
|
|||||||
Cash
at beginning of year
|
2,294,746
|
306,137
|
|||||
|
|||||||
Cash
at end of year
|
$
|
1,295,266
|
$
|
2,294,746
|
|||
|
|||||||
Cash
paid during the twelve months ended December 31:
|
|||||||
|
|||||||
|
2005
|
2004
|
|||||
Interest
|
$
|
22,703
|
$
|
11,625
|
|||
|
|||||||
Income
Taxes
|
22,015
|
--
|
|||||
|
|||||||
The
accompanying notes are an integral part of these financial
statements.
|
|||||||
|
|
|
2005
|
2004
|
|
|||
Raw
materials (net of reserves)
|
|
$
|
1,139,730
|
|
$
|
705,188
|
|
Work
in process
|
|
|
1,267,991
|
|
|
742,289
|
|
Finished
goods
|
|
|
589,111
|
|
|
554,160
|
|
|
|
|
|
|
|
||
Total
|
|
$
|
2,996,832
|
|
$
|
2,001,637
|
|
|
2005
|
2004
|
|||||
Raw
materials
|
$
|
317,614
|
$
|
317,615
|
|||
Allowance
for excess or obsolete parts
|
(
317,614
|
)
|
(193,252
|
)
|
|||
Total
|
$
|
--
|
$
|
124,363
|
|
|
2005
|
2004
|
|
|||
Net
earnings:
|
|
|
|
|
|
||
As
reported
|
|
$
|
406
|
|
$
|
1,512
|
|
Deduct:
Compensation expense --
|
|
|
|
|
|
|
|
fair
value method
|
|
|
(372
|
)
|
|
(522
|
)
|
Pro
forma
|
|
$
|
34
|
|
$
|
990
|
Basic
net earnings per share:
|
|
|
|
|
|
||
As
reported
|
|
$
|
.03
|
|
$
|
.11
|
|
Pro
forma
|
|
$
|
.00
|
|
$
|
(.07
|
)
|
|
|
|
|
|
|
||
Diluted
net earnings per share:
|
|
|
|
|
|
||
As
reported
|
|
$
|
.03
|
|
$
|
.09
|
|
Pro
forma
|
|
$
|
.00
|
|
$
|
(.06
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
2005
|
2004
|
Risk-free
interest rate
|
4.5%
|
4.18%
|
Expected
dividend yield
|
0.00%
|
0.00%
|
Expected
stock price volatility
|
30%
|
43%
|
Expected
option life
|
5
years
|
10
years
|
|
|
2005
|
2004
|
|
|||
Trade
accounts receivable
|
|
$
|
2,495,457
|
|
$
|
2,131,445
|
|
Less:
allowance for doubtful accts
|
|
|
(
119,490
|
)
|
|
(
112,392
|
)
|
allowance
for discounts
|
|
|
(
59,207
|
)
|
|
(
64,766
|
)
|
|
|
|
|
|
|
|
|
Trade
accounts receivable, net
|
|
$
|
2,316,760
|
|
$
|
1,954,287
|
|
|
2005
|
2004
|
|||||
|
|
|
|||||
Equipment
|
$
|
1,297,261
|
$
|
992,542
|
|||
Building
|
791,618
|
573,736
|
|||||
Furniture
and Fixtures
|
1,045,835
|
969,948
|
|||||
Leasehold
Improvements
|
731,001
|
626,804
|
|||||
Molds
|
661,462
|
516,689
|
|||||
|
4,527,177
|
3,679,719
|
|||||
|
|||||||
Less:accumulated
depreciation
|
(1,931,536
|
)
|
(1,563,395
|
)
|
|||
|
|||||||
Net
property, plant, and equipment
|
$
|
2,595,641
|
$
|
2,116,324
|
|||
|
2006
|
|
$
|
141,952
|
|
2007
|
|
|
135,308
|
|
2008
|
|
|
115,150
|
|
2009
|
|
|
-0-
|
|
2010
|
|
|
-0-
|
|
|
|
$
|
392,410
|
|
|
|
2005
|
2004
|
|
|||
Indefinite
life assets:
|
|
|
|
|
|
||
Brand
name/Trademark (life indefinite)
|
|
$
|
1,509,662
|
|
$
|
1,509,662
|
|
Other
intangibles:
|
|
|
|
|
|
||
License
rights (20yr life)
|
|
|
280,000
|
|
|
350,000
|
|
Purchased
technology (5 yr life)
|
|
$
|
280,764
|
|
$
|
278,763
|
|
Less:
Accumulated amortization
|
|
|
(247,101)
|
|
(190,191
|
)
|
|
|
|
|
|
|
|
||
Net
carrying amount
|
|
$
|
33,663
|
|
$
|
88,572
|
|
|
|
2005
|
2004
|
|
|||
Mortgage
payable
|
|
$
|
348,328
|
|
$
|
379,994
|
|
Term
loan
|
|
|
--
|
|
|
--
|
|
Line
of credit- bank
|
|
|
--
|
|
|
--
|
|
|
|
$
|
348,328
|
|
$
|
379,994
|
|
Year
|
|
Amount
|
|
|
|
|
|
|
|
2006
|
|
$
|
348,328
|
|
2007
|
0
|
|||
2008
|
0
|
|||
2009
|
0
|
|||
2010
|
0
|
|||
$
|
348,328
|
|
2005
|
2004
|
||
|
Weighted
|
Weighted
|
||
|
average
|
average
|
||
|
Number
of
|
exercise
|
Number
of
|
exercise
|
|
Shares
|
price
|
Shares
|
price
|
|
|
|
|
|
Balance
January 1,
|
3,951,200
|
1.15
|
3,988,800
|
1.00
|
|
|
|
||
Exercised
|
(178,600)
|
.77
|
(397,600)
|
.74
|
Cancelled
& forfeited
|
(31,230)
|
.50
|
(
10,000)
|
.50
|
Granted
|
427,500
|
2.25
|
370,000
|
2.32
|
|
|
|
||
Balance
December 31,
|
4,168,870
|
1.25
|
3,951,200
|
1.13
|
Number
of Options
Currently
Exercisable
|
Weighted
Average
Remaining
Estimated Life
|
Exercise
Price
|
456,000
|
7.5
|
$
3.25
|
95,000
|
7.5
|
1.30
|
113,000
|
2.0
|
1.125
|
50,000
|
2.0
|
1.15
|
1,238,400
|
2.5
|
.75
|
475,000
|
7.0
|
.70
|
1,013,970
|
5.5
|
.50
|
35,000
|
8.5
|
2.95
|
215,000
|
8.5
|
2.13
|
60,000
|
8.5
|
2.41
|
417,500
|
4.6
|
225
|
4,168,870
|
4.6
|
1.25(a)
|
|
|
|
|
|
|
||
|
|
2005
|
2004
|
|
|||
|
|
|
|
|
|
||
Accounts
receivable(allowances)
|
|
$
|
178,697
|
|
$
|
177,158
|
|
Inventories(reserves)
|
|
|
990,314
|
|
|
1,011,060
|
|
Net
operating loss carry forwards
|
|
|
2,220,000
|
|
|
2,392,000
|
|
Patent
rights, primarily due to
|
|
|
|
|
|
||
Amortization
|
|
|
(163,245)
|
|
(118,439
|
)
|
|
|
|
|
|
|
|||
Total
gross deferred tax assets
|
|
|
3,225,766
|
|
3,461,779
|
|
|
Less:
Valuation allowance
|
|
|
(2,839,566
|
)
|
|
(3,075,579
|
)
|
|
|
|
|
|
|
||
Net
deferred tax assets - current
|
|
$
|
386,200
|
|
$
|
386,200
|
|
Year
loss
|
Expiration
|
Loss
|
Estimated
|
Incurred
|
Date
|
Amount
|
Tax
Asset
|
|
|
|
|
1992
|
2012
|
797,000
|
$
279,000
|
1993
|
2013
|
465,000
|
163,000
|
1994
|
2014
|
1,197,000
|
419,000
|
1995
|
2015
|
637,000
|
223,000
|
1998
|
2018
|
548,000
|
192,000
|
1999
|
2019
|
2,184,000
|
764,000
|
2002
|
2022
|
515,000
|
180,000
|
|
|
|
|
Total
|
|
$
6,343,000
|
$
2,220,000
|
Tax
at statutory rate
|
35.0%
|
State
income taxes, net of U.S. federal benefit
|
2.4%
|
Tax
benefit of loss carry forward
|
(37.2%)
|
|
|
Effective
tax rate
|
-0-%
|
Summary
information by segment area for years ended December 31, 2005 and
2004
were as follows:
|
||||
(in
thousands)
|
|
|
|
|
|
Cauteries
|
Electrosurgical
|
Other
|
Total
|
|
|
|
|
|
Year
ended December 31, 2005
|
||||
Net
sales
|
5,462
|
12,191
|
2,558
|
20,211
|
Interest
income
|
13
|
28
|
6
|
47
|
Interest
expense
|
6
|
14
|
3
|
23
|
Depreciation
& Amortization
|
160
|
356
|
78
|
594
|
Income
taxes
|
44
|
98
|
22
|
164
|
Income
tax benefit
|
35
|
79
|
18
|
132
|
Segment
net earnings(basic)
|
109
|
244
|
53
|
406
|
Total
Assets
|
3,178
|
7,063
|
1,530
|
11,771
|
Capital
expenditures
|
245
|
545
|
118
|
908
|
Year
ended December 31, 2004
|
|
|
|
|
Net
sales
|
5,460
|
12,684
|
2,351
|
20,495
|
Interest
income
|
1
|
2
|
--
|
3
|
Interest
expense
|
4
|
9
|
1
|
14
|
Depreciation
& amortization
|
158
|
186
|
51
|
395
|
Income
taxes
|
194
|
216
|
46
|
456
|
Income
tax benefit
|
(194)
|
(216)
|
(46)
|
(456)
|
Segment
net earnings(basic)
|
538
|
602
|
127
|
1,267
|
Total
assets
|
2,975
|
6,832
|
1,212
|
11,019
|
Capital
expenditures
|
164
|
375
|
67
|
606
|
Other
Income
|
66
|
152
|
27
|
245
|
|
|
|
|
|
|
Net
Sales
|
Long
Lived Assets
|
|||||
Year
ended December 31, 2005
|
|
|
|||||
|
|
|
|||||
United
States
|
$
|
16,830
|
$
|
2,545
|
|||
Europe
|
1,460
|
50
|
|||||
Asia
|
759
|
||||||
South
America
|
558
|
||||||
Other
|
604
|
||||||
|
|||||||
Total
|
$
|
20,211
|
$
|
2,595
|
|||
|
|||||||
|
|||||||
Year
ended December 31, 2004
|
|||||||
United
States
|
$
|
17,506
|
$
|
2,107
|
|||
Europe
|
1,222
|
60
|
|||||
Asia
|
635
|
||||||
South
America
|
586
|
||||||
Other
|
546
|
||||||
|
|||||||
Total
|
$
|
20,495
|
$
|
2,167
|
|||
|
|
|
2005
|
2004
|
|
|||
|
|
|
|
|
|
||
Total
assets
|
|
$
|
622
|
|
$
|
411
|
|
Total
liabilities
|
|
|
10
|
|
|
-0-
|
|
Net
property, plant and equipment
|
|
|
100
|
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
2005
|
2004
|
|
|||
Amounts:
|
|
|
|
|
|
||
Revenue
from development in progress
|
|
$
|
368,334
|
|
$
|
230,120
|
|
|
|
|
|
|
|
|
|
Revenues
included in Gross Sales
|
|
$
|
368,334
|
|
$
|
230,120
|
|
|
|
|
|
|
|
||
Cost
of Research and Development contracts
|
|
|
|
|
|
||
included
in gross profit
|
|
$
|
368,334
|
|
$
|
230,120
|
|
Exhibit
4.2
|
Registration
Rights Agreement dated May 8, 1998 (1)
|
Exhibit
4.3
|
Assignment
of Registration Rights Agreement dated September, 2004 (2)
|
Exhibit
10.1
|
Joint
Venture Agreement dated February 25, 2000
Between
Bovie Medical Corporation and Jump Agentur fur
Elektrotechnik
GmBH
(3)
|
Exhibit
10.2
|
Agreement
between Bovie Medical Corporation and Arthrex Inc. dated June 2002
(4)
|
Exhibit
10.3
|
Distribution
and Service Center Agreement between Bovie Medical Corp and
Symbol Medical
Limited dated December 31, 2004
(5)
|
Exhibit
10.4
|
Employment
Agreement- Andrew Makrides (6)
|
Exhibit
10.5
|
Employment
Agreement-Robert J. Saron (7)
|
Exhibit
10.6
|
Employment
Agreement-Moshe Citronowicz (8)
|
Exhibit
10.7
|
Amended
Employment Agreement between Bovie and Andrew Makrides dated as
of January
6, 2004 (9)
|
Exhibit
10.8
|
Amended
Employment Agreement between Bovie and J. Robert Saron dated as
of January
6, 2004 (10)
|
Exhibit
10.9
|
Amended
Employment Agreement between Bovie and Moshe Citronowciz dated
as of
January 6, 2004 (11)
|
Exhibit
10.10
|
License
Agreement between Bovie and Emergency Medicine Innovations, LLC
dated
October 22, 2004 (12)
|
_____________________
|
|